Literature DB >> 35308022

Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia.

Nanxiang Wang1, Wenhui Ji1, Lan Wang1, Wanxia Wu1, Wei Zhang1, Qiong Wu1, Wei Du1, Hua Bai2, Bo Peng2, Bo Ma3, Lin Li1.   

Abstract

l-Asparaginase (l-ASNase is the abbreviation, l-asparagine aminohydrolase, E.C.3.5.1.1) is an enzyme that is clinically employed as an antitumor agent for the treatment of acute lymphoblastic leukemia (ALL). Although l-ASNase is known to deplete l-asparagine (l-Asn), causing cytotoxicity in leukemia cells, the specific molecular signaling pathways are not well defined. Because of the deficiencies in the production and administration of current formulations, the l-ASNase agent in clinical use is still associated with serious side effects, so controlling its dose and activity monitoring during therapy is crucial for improving the treatment success rate. Accordingly, it is urgent to summarize and develop effective analytical methods to detect l-ASNase activity in treatment. However, current reports on these detection methods are fragmented and also have not been systematically summarized and classified, thereby not only delaying the investigations of specific molecular mechanisms, but also hindering the development of novel detection methods. Herein, in this review, we provided a detailed summary of the l-ASNase structures, antitumor mechanism and side effects, and current detection approaches, such as fluorescence assays, colorimetric assays, spectroscopic assays and some other assays. All of them possess unique advantages and disadvantages, so it has been difficult to establish clear criteria for clinical application. We hope that this review will be of some value in promoting the development of l-ASNase activity detection methods. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2022        PMID: 35308022      PMCID: PMC8864486          DOI: 10.1039/d1md00344e

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  90 in total

1.  Dynamics of a mobile loop at the active site of Escherichia coli asparaginase.

Authors:  H P Aung; M Bocola; S Schleper; K H Röhm
Journal:  Biochim Biophys Acta       Date:  2000-09-29

2.  Screening and optimizing fermentation production of l-asparaginase by Aspergillus terreus strain S-18 isolated from the Brazilian Caatinga Biome.

Authors:  W R V da Rocha; T A Costa-Silva; G S Agamez-Montalvo; V A Feitosa; S E F Machado; G M de Souza Lima; A Pessoa-; H S Alves
Journal:  J Appl Microbiol       Date:  2019-03-19       Impact factor: 3.772

3.  Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy.

Authors:  A L Swain; M Jaskólski; D Housset; J K Rao; A Wlodawer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

4.  L-Asparaginase of Saccharomyces cerevisiae: an extracellular Enzyme.

Authors:  P C Dunlop; R J Roon
Journal:  J Bacteriol       Date:  1975-06       Impact factor: 3.490

5.  Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase.

Authors:  K Aghaiypour; A Wlodawer; J Lubkowski
Journal:  Biochemistry       Date:  2001-05-15       Impact factor: 3.162

6.  How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.

Authors:  Leiah J Brigitha; Rob Pieters; Inge M van der Sluis
Journal:  Eur J Cancer       Date:  2021-09-15       Impact factor: 9.162

7.  Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.

Authors:  Lewis B Silverman; Jeffrey G Supko; Kristen E Stevenson; Christina Woodward; Lynda M Vrooman; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdière; Bruno Michon; Marshall Schorin; Cindy L Schwartz; Jane E O'Brien; Harvey J Cohen; Stephen E Sallan
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

8.  A catalytic role for threonine-12 of E. coli asparaginase II as established by site-directed mutagenesis.

Authors:  E Harms; A Wehner; H P Aung; K H Röhm
Journal:  FEBS Lett       Date:  1991-07-08       Impact factor: 4.124

9.  Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Authors:  Andrew E Place; Kristen E Stevenson; Lynda M Vrooman; Marian H Harris; Sarah K Hunt; Jane E O'Brien; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Steven E Lipshultz; Jeffery L Kutok; Traci M Blonquist; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  Lancet Oncol       Date:  2015-11-06       Impact factor: 41.316

Review 10.  L-asparaginase production review: bioprocess design and biochemical characteristics.

Authors:  Daniel Castro; Ana Sofia C Marques; Mafalda R Almeida; Gabriela B de Paiva; Heitor B S Bento; Danielle B Pedrolli; Mara G Freire; Ana P M Tavares; Valéria C Santos-Ebinuma
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-01       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.